AAAna Alonso

Ana Alonso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Alonso has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)

    by Óscar Fernández, Xavier Montalban, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, et al.

    The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of this edition was to present the latest developments in MS regarding the update of diagnostic criteria, advanced neuroimaging techniques, the role of Epstein-Barr virus, remyelination mechanisms and biomarkers. In the therapeutic field, emerging treatments were addressed, such as new monoclonal antibodies and chimeric antigen receptor T cells (CAR-T), the management of elderly patients and the risks associated with high-efficacy therapies. This article is the second of a two-part series (I and II). The article reviews recent data on disease progression and on the concept of progression independent of relapse activity (PIRA), including the definition, among those published, that leads to balanced incidence and persistence in PIRA rates. Certain neuropathological and imaging aspects are reviewed, and, with regard to serum biomarkers, it is emphasised that neurofilament light chain (NfL) is a marker of acute damage that is not specific to MS, and that the challenge lies in establishing a value that differentiates it from other diseases. It is also discussed whether the low sensitivity of NfL for predicting progression lies in the z-score used in clinical practice, and the usefulness of glial fibrillary acidic protein (GFAP) in combination with NfL to refine the assessment of chronic progressive damage. The importance of age in MS is indisputable. The elderly patient with MS has a greater number of comorbidities and is more vulnerable to certain treatments. Menopause is a normal but expected physiological transition of female ageing that may trigger or aggravate certain health problems, and whose symptoms should not be confused with worsening of the disease. As for cognitive impairment in MS, the latest developments and expert opinions that could help improve its identification and monitoring are summarised. Much of this part II article focuses on summarising the key advances in emerging therapies and treatment prospects in related diseases, without overlooking the risks associated with very high-efficacy therapies and the possible risk-prevention strategies. Finally, as important findings that translate into clinical practice, the notable improvement in diagnosis with the new 2024 McDonald criteria stands out, despite the barriers to accessing paraclinical tests in certain populations. Overall, the data reviewed, together with those gathered in part I, reflect the research effort to advance the understanding of the disease from multiple complementary perspectives, which is transforming the care of patients with MS.

  • Open Access

    XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)

    by Óscar Fernández, Xavier Montalban, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, et al.

    The 18th edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 17–18 October 2025 in Madrid, bringing together Spanish neurologists specialising in multiple sclerosis (MS), who presented the most relevant advances discussed at the ECTRIMS congress held a few days earlier in Barcelona. The aim of the meeting was to summarise the latest developments in the pathogenesis, new diagnostic criteria and biomarkers of MS. This article is the first of a two-part series (I and II) that reviews recent data on cell trafficking into the central nervous system, highlighting the functional heterogeneity of the brain endothelium, the molecular mechanisms regulating leukocyte infiltration and the differential role of macrophages and resident microglia in tissue damage and chronic inflammation. The evidence supporting the role of Epstein-Barr virus as a necessary risk factor in MS is presented, together with the therapeutic and preventive implications from studies of antiviral therapies, cell-based therapies and vaccines. Regarding diagnosis, the new criteria for neuromyelitis optica spectrum disorders are addressed, with particular attention to the molecular heterogeneity of double-seronegative forms, as well as the update of the magnetic resonance imaging (MRI) guidelines following the 2024 revision of the McDonald criteria. Advances in the neuroimaging of chronic active inflammation, quantitative spinal cord imaging and the concept of spinal cord reserve are highlighted. The growing role of artificial intelligence applied to MRI for the early prediction of progression and treatment response is also reviewed. Finally, advances in remyelination mechanisms and in biomarkers are presented, underscoring the value of multimodal and longitudinal approaches for prognostic stratification and treatment monitoring. Overall, the data reviewed reflect a change into a more integrated and predictive understanding of MS, with direct implications for early diagnosis, treatment personalisation and the design of future clinical trials.

  • Open Access

    Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study

    by Celia Oreja-Guevara, Irene Gómez-Estévez, Laura Agüado García, Jesus Martín Martínez, Montserrat Gómez Gutiérrez, Francisco Gascón Giménez, Eduardo Agüera Morales, Virginia Meca-Lallana, Francisco Javier Barrero Hernández, Vicente González Quintanilla, et al.

    Background: Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited. Objective: To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting. Design: Non-interventional/observational, retrospective, multicenter study (28 centers). Methods: Patients (⩾18 years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24 months before and 12 months after siponimod treatment. Results: In total, 210 participants were included (mean age: 52.5 ± 8.6 years; females: 71.0%). At treatment initiation, the mean Expanded Disability Status Scale (EDSS) score was 5.7 ± 1.2. The mean time since multiple sclerosis diagnosis and the median time since active SPMS diagnosis were 16.7 ± 8.9 years and 1.3 (0.3; 4.4) years, respectively. Common comorbidities included psychiatric disorders and dyslipidemia (20.6%, each). Regarding working status, 55.9% with available information showed incapacity for work. Prior to siponimod, 44.3% received highly effective therapies: fingolimod (20.5%), rituximab (9.5%), ocrelizumab (5.2%), natalizumab (4.8%), and alemtuzumab (2.4%). After 1 year, 82.8% of the patients remained stable in terms of disability progression, 94.3% were free of relapses, and 85.7% did not present radiological disease activity; 46.2% experienced adverse events, 8.6% experienced serious adverse events, and 26 (12.4%) patients discontinued permanently. Conclusion: In the study cohort, pwSPMS had high disability scores and comorbidities; more than half were unable to work, and over 40% had previously received high-efficacy therapies. After 1 year of siponimod treatment, most pwSPMS showed no signs of disease activity, with stabilized EDSS scores and relapses and new T2 or gadolinium-T1 lesions, as well as a favorable safety profile.

  • Open Access

    XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (I)

    by Óscar Fernández, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, Tamara Castillo-Triviño, et al.

    Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To present new developments in neurodegeneration and progression, the prodromal phase and diagnosis, the clinical use of biomarkers and neuroimaging, as well as the current role of patient-reported outcomes and digital monitoring. Highlights on the risk of infections and comorbidities in MS are also summarized. Content and Conclusions: In active MS lesions, there is no correlation between the myeloid cell phenotype and remyelination, while memory astrocytes, regulated by the CLEC16A gene, are present in chronic active lesions. Gray matter atrophy is associated with disability and progression independent of relapses, whereas cervical spinal cord atrophy predicts the prognosis of progressive forms and may lead to earlier diagnosis. Healthcare resource utilization increases in the years preceding the first demyelinating event, and although prodromal symptoms are highly variable, they are useful in identifying risk factors for the disease. The new McDonald criteria will facilitate the diagnosis of MS in patients with a radiologically isolated syndrome. Glial fibrillary acidic protein complements neurofilaments, and both biomarkers could soon be standardized for use in clinical practice; paramagnetic rim lesions and slowly expanding lesions are promising imaging markers. In another area, patient-reported health outcomes are valuable, although they are subject to selection bias and the need to define boundaries for their use. Finally, the risk of infections increases before diagnosis and may worsen with certain treatments. Comorbidities in MS should be managed as an integral part of disease management.

  • Open Access

    XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II)

    by Óscar Fernández, Adrián Arés, Eduardo Agüera, Yolanda Aladro, Ana Alonso, Rafael Arroyo, Luis Brieva, Carmen Calles, Ana Belén Caminero, Tamara Castillo-Triviño, et al.

    Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4–5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen. Aim: To summarize the main new findings in clinical research on MS. Content and Conclusions: The immunological changes throughout life and in response to MS treatments were analyzed. The impact of aging was also discussed, along with new developments related to symptomatic treatments, physical exercise, fatigue, and sleep disorders. Emphasis was placed on addressing ongoing challenges in measuring therapeutic failure and managing treatments for secondary progressive MS. Additionally, data from registries and real-world studies were presented, including new analyses on cladribine, highlighting the need to collect safety information. Regarding immune reconstitution therapies, mechanisms of action and the immune system’s reconstitution process after treatment were explored. Finally, regarding therapeutic innovations, the first results from chimeric antigen receptor (CAR)-T cell therapy studies in MS were reported, representing a promising advancement in disease management.

  • Patient experience in healthcare interventions: PROM and PREM evaluation in patients with multiple sclerosis after switching administration route of natalizumab

    by Cristina Fernández-Cuerva, Aranzazu Linares-Alarcon, María José Morales Lara, Ana Maria Alonso Torres, Virginia Reyes-Garrido, Patricia Urbaneja, Alvaro Sanchez-Guijo Benavente

    Natalizumab is a disease-modifying drug approved for the treatment of relapsing-remitting multiple sclerosis. It is available as vials for intravenous administration and in 2021 was approved as syringes for the subcutaneous route; both have to be administered in a daycare unit in the hospital. Some studies have addressed the cost-effectiveness of changing the route of administration from intravenous to subcutaneous, but the Patient Reported Outcomes Measures (PROMs) and Patient Reported Experience Measures (PREMs) regarding this change have not yet been studied. The objective of this work is to assess switching from the intravenous route to the subcutaneous route in our centre through the evaluation of PROMs and PREMs. An implementation study was conducted to evaluate the PROMs and PREMs of patients after changing the route of administration of natalizumab from intravenous to subcutaneous. An ad hoc questionnaire was developed, in consensus with the neurology team, which was performed by telephone to patients who agreed to participate in the study. The questionnaire was divided into three fields: pain during administration for both routes, patient satisfaction and adverse events of subcutaneous administration. Forty-seven patients participated in the study. They reported greater pain with subcutaneous administration, but no patient defined it as unbearable. The subcutaneous route was preferred by 97.9% of patients, who stated that this route of administration was less time consuming than the intravenous route. Regarding adverse events, 94.5% patients reported none, and itching was the most common local adverse event reported (29.8%). This is a novel experience in our setting of collaboration between pharmacy and neurology services to implement PROMs and PREMs in the evaluation of a health intervention. Patients expressed satisfaction with changing the route of administration of natalizumab. This study has enabled us to detect interventions to use to achieve a better patient experience.


  • Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study

    by Romain Marignier, Javier Villacieros-Álvarez, Carmen Espejo, Georgin Arrambide, Nicolás Fissolo, Lucía Gutiérrez, Alessandro Dinoto, Patricia Mulero, Laura Rubio-Flores, Pablo Nieto, et al.

    Background: Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD). However, their interest in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains unclear. Our aim was to characterise sNfL and sGFAP profile and analyse their usefulness in predicting relapses and disability in MOGAD. Methods: Retrospective study of adult MOGAD patients with serum samples collected at baseline (=3 months from disease onset) and follow-up (>6 months from baseline sample). sNfL and sGFAP were analysed using Simoa HD-1, and values were compared across time-points. The association between biomarkers and clinical variables and their predictive value for disability and relapses were analysed. Results: Eighty-nine MOGAD patients were included. Baseline sNfL and sGFAP values were high at baseline and decreased over time (p<0.001, p=0.027, respectively). sNfL and sGFAP values were associated with Expanded Disability Status Scale (EDSS) at attacks (ß 0.15 (0.06; 0.25), p=0.002; ß 0.14 (0.07; 0.21), p<0.001, respectively) and were lower in optic neuritis presentations (ß -0.69 (-1.18; -0.19), p=0.007; ß -0.42 (-0.76; -0.08), p=0.016). Biomarker deltas[?] (baseline values – second samples values) were associated with ?EDSS (initial EDSS - final EDSS) (?sNfL ß 0.52 (0.01; 1.04), p=0.046; ?sGFAP ß 1.07 (0.38; 1.75), p=0.003). Finally, sNfL values independently predicted the risk of relapses (HR 2.06 (1.41; 3.01), p<0.001). Conclusions: Our results on sNfL and sGFAP suggest initial neuro-axonal and astrocytic damage in MOGAD and the utility of these biomarkers at onset and follow-up in predicting clinical recovery and relapses.


  • Open Access

    Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

    by Julia Sabin, Elisa Salas, Jesús Martín-Martínez, Antonio Candeliere-Merlicco, Francisco Javier Barrero, Ana Alonso, José Luis Sánchez-Menoyo, Laura Borrega, María Rodríguez-Rodríguez, Montserrat Gómez-Gutiérrez, et al.

    A multicenter study involving 204 adults with relapsing-remitting multiple sclerosis (RRMS) assessed the dimensionality and item characteristics of the Mishel-Uncertainty of Illness Scale (MUIS), a generic self-assessment tool. Mokken analysis identified two dimensions in the MUIS with an appropriate item and overall scale scalability after excluding nonclassifiable items. A refined 12-item MUIS, employing a grade response model, effectively discriminated uncertainty levels among RRMS patients (likelihood ratio test p-value = .03). These findings suggest the potential value of the 12-item MUIS as a reliable measure for assessing uncertainty associated with the course of illness in RRMS.


  • Open Access

    Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    by Susana Sainz de la Maza, Rocío Gómez-Ballesteros, Mónica Borges, Jesús Martín-Martínez, Javier Sotoca, Ana Alonso, Ana B Caminero, Laura Borrega, José L Sánchez-Menoyo, Francisco J Barrero-Hernández, et al.

    Disability accrual is mainly driven by progression independent of relapse activity, which is present even in early stages of relapsing-remitting multiple sclerosis (RRMS) and sometimes overlooked. This multicenter, non-interventional study evaluated whether patient-reported outcomes measures (PROMs) could capture disability in 189 early-stage RRMS patients (mean age: 36.1 ± 9.4 years, 71.4% female, mean disease duration: 1.4 ± 0.8 years, median EDSS: 1.0). The 9-Hole Peg Test (9-HPT), NeuroQoL Upper Extremity (NeuroQoL-UE), Timed 25-Foot Walk (T25-FW), Multiple Sclerosis Walking Scale (MSWS-12), Symbol Digit Modalities Test (SDMT), and Perceived Deficits Questionnaire (PDQ-5) were used to assess hand function, gait, and cognition, respectively. These functions were at least mildly affected in this early-stage population, finding significant correlations between PROMs and clinical assessments. PROMs could enable early-stage RRMS patients to communicate their perceived disability in different domains, assisting clinicians in disease monitoring and decision making.